Results 131 to 140 of about 847 (163)
Some of the next articles are maybe not open access.
Canadian Journal of Health Technologies
Reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform nonbinding recommendations that help guide the reimbursement decisions of Canada’s federal, provincial, and territorial governments, with the ...
openaire +1 more source
Reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform nonbinding recommendations that help guide the reimbursement decisions of Canada’s federal, provincial, and territorial governments, with the ...
openaire +1 more source
Abnormal dreams and night terrors with atogepant: A case series
American Journal of Health-System PharmacyAbstract Purpose To describe a potential emerging neuropsychiatric adverse effect, abnormal dreams or night terrors, associated with atogepant (a calcitonin gene–related peptide receptor antagonist) observed in 4 patients treated at a tertiary headache clinic, and to place these observations in
Jason To +4 more
openaire +2 more sources
Atogepant (Qulipta®) for migraine prevention
Trends in Pharmacological Sciences, 2022Debbie L. Hay +2 more
openaire +4 more sources
Atogepant for the prophylaxis of migraine in adults
PrescriberAtogepant (Aquipta) is a new oral CGRP‐receptor antagonist indicated for the prophylaxis of migraine in adults. This article discusses its indication, efficacy and adverse effects.
openaire +1 more source